Methods and compositions for the treatment of cancer
AssigneeChildren's Medical Center Corporation
InventorsJudy Lieberman, Ying Zhang
Life of this patent
Estimating the term…
Abstract
The technology described herein is directed to improved chimeric molecules for, e.g, the treatment of cancer. As described herein, the inventors have developed novel chimeric aptamer-siRNA molecules (AsiCs) which demonstrate improved efficacy over existing AsiCs and which can successfully synergize in treating cancer. These AsiC's target cancer cell markers to direct therapeutic siRNA molecules specifically to cancer cells, increasing delivery efficacy and therapeutic effectiveness while reducing the potential for side effects.
Claims20
A pharmaceutical composition, kit, or combination comprising at least two different chimeric molecules,
- wherein each chimeric molecule comprises an EpCAM-binding aptamer domain and an inhibitory nucleic acid domain comprising an siRNA which inhibits the expression of a gene selected from the group consisting of:
- CD47;
- UPF2;
- PD-L1;
- and MCL1;
- wherein the at least two different chimeric molecules collectively comprise inhibitory nucleic acid domains that inhibit the expression of each of CD47;
- UPF2;
- PD-L1;
- and MCL1.
Dependencies are inferred from the claim text.